| Basics |
Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals Inc, formerly Inotek Pharmaceuticals Corp, is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye.
|
| IPO Date: |
February 18, 2015 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$359.3M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.60 | 3.05%
|
| Avg Daily Range (30 D): |
$0.09 | 2.88%
|
| Avg Daily Range (90 D): |
$0.09 | 2.73%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.76M |
| Avg Daily Volume (30 D): |
1.71M |
| Avg Daily Volume (90 D): |
2.84M |
| Trade Size |
| Avg Trade Size (Sh.): |
94 |
| Avg Trade Size (Sh.) (30 D): |
163 |
| Avg Trade Size (Sh.) (90 D): |
199 |
| Institutional Trades |
| Total Inst.Trades: |
2,697 |
| Avg Inst. Trade: |
$2.02M |
| Avg Inst. Trade (30 D): |
$1M |
| Avg Inst. Trade (90 D): |
$1.37M |
| Avg Inst. Trade Volume: |
.11M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.32M |
| Avg Closing Trade (30 D): |
$.67M |
| Avg Closing Trade (90 D): |
$1.03M |
| Avg Closing Volume: |
132.1K |
|
|
| News |
Oct 23, 2025 @ 10:03 PM
ROCKET ALERT: Bragar Eagel & Squire, P.C. is Inves...
Source: Bragar Eagel & Squire, P.C.
|
Aug 11, 2025 @ 4:00 PM
DEADLINE ALERT for RCKT, DDD, TEM, RDDT: Law Offic...
Source: Law Offices Of Howard G. Smith
|
Aug 10, 2025 @ 3:38 PM
RCKT DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR CO...
Source: Rosen Law Firm
|
Aug 8, 2025 @ 4:38 PM
Deadline Soon: Rocket Pharmaceuticals, Inc. (RCKT)...
Source: Business Wire
|
Aug 7, 2025 @ 11:45 PM
MONDAY INVESTOR DEADLINE: Robbins Geller Rudman & ...
Source: Robbins Geller Rudman & Dowd Llp
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
|
$-.45
|
$-.62
|
|
Diluted EPS
|
|
$-.45
|
$-.62
|
|
Revenue
|
$
|
$ M
|
$ M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$
|
$ -50.33M
|
$ -68.92M
|
|
Operating Income / Loss
|
$
|
$ -52.25M
|
$ -71.15M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$
|
$ 43.13M
|
$ -130.81M
|
|
PE Ratio
|
|
|
|
|
|
|
